Lucjan Wyrwicz, MD, PhD, Maria Sklodowska-Curie National Cancer Research Institute, Warsaw, Poland, discusses findings from the Phase III KEYNOTE-859 trial (NCT03675737) of pembrolizumab plus chemotherapy in patients with gastric/gastroesophageal junction (G/GEJ) cancer. The primary endpoint of overall survival was met in all subgroups, and time to second progression (PFS2) was additionally consistent with progression-free survival (PFS) rates. The results from the study confirms that there is a role for checkpoint inhibition in this setting. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
